This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Bariatric surgery for obesity in type 2 diabetes

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Obesity as a causative factor for type 2 diabetes

A large prospective longitudinal study has shown that weight gain is associated with an increased risk of type II diabetes mellitus (1).

The study followed 114,281 female nurses in the USA.

A weight increase of 5-7.9 kg during the study was associated with an approximately two-fold increase in risk for type II diabetes. A weight increase of 8-10.9 kg resulted in a three-fold increase in risk.

With respect to the UK (2):

  • likelihood and severity of type 2 diabetes are closely linked with body mass index (BMI)
    • a seven times greater risk of diabetes in obese people compared to those of healthy weight, with a threefold increase in risk for overweight people
    • currently 90% of adults with type 2 diabetes are overweight or obese
    • people from black, Asian and other minority ethnic groups are at an equivalent risk of type 2 diabetes at lower BMI levels than white European populations
    • 62% of adults were overweight or obese in England in 2012
    • 6% of people aged 17 years or older had diagnosed diabetes in England in 2013

Surgical treatment of obesity in patients with diabetes

  • bariatric surgery has been shown to induce the remission of diabetes or to reduce the need for medications with durable long-term results in morbidly obese patients (3,4,5,6).

Evidence of effectiveness of bariatric surgery in the treatment of type 2 diabetes mellitus (T2DM)

  • a meta-analysis compared with non-surgical treatment of obesity, bariatric surgery leads to greater body weight loss and higher remission rates of type 2 diabetes and metabolic syndrome
    • included 11 studies with 796 individuals (range of mean body mass index at baseline 30-52)
      • individuals allocated to bariatric surgery lost more body weight (mean difference -26 kg (95% confidence interval -31 to -21)) compared with non-surgical treatment, had a higher remission rate of type 2 diabetes (relative risk 22.1 (3.2 to 154.3) in a complete case analysis; 5.3 (1.8 to 15.8) in a conservative analysis assuming diabetes remission in all non-surgically treated individuals with missing data) and metabolic syndrome (relative risk 2.4 (1.6 to 3.6) in complete case analysis; 1.5 (0.9 to 2.3) in conservative analysis), greater improvements in quality of life and reductions in medicine use (no pooled data)
      • plasma triglyceride concentrations decreased more (mean difference -0.7 mmol/L (-1.0 to -0.4) and high density lipoprotein cholesterol concentrations increased more (mean difference 0.21 mmol/L (0.1 to 0.3))
      • changes in blood pressure and total or low density lipoprotein cholesterol concentrations were not significantly different
      • there were no cardiovascular events or deaths reported after bariatric surgery
        • most common adverse events after bariatric surgery were iron deficiency anaemia (15% of individuals undergoing malabsorptive bariatric surgery) and reoperations (8%)

  • a cohort of 217 patients with T2DM who underwent bariatric surgery between 2004 and 2007 and had at least 5-year follow-up were assessed. Complete remission was defined as glycated hemoglobin (A1C) less than 6% and fasting blood glucose (FBG) less than 100 mg/dL off diabetic medications (4)
    • demonstrated that 24% of all patients and 31% of gastric bypass patients achieved long-term complete remission with an A1C less than 6.0% and that 27% of the gastric bypass patients sustained that level of glycemic control off medication continuously for more than 5 years
    • as seen in other studies this study demonstrated that (Roux en Y gastric bypass) RYGB had a higher long-term rate of diabetes remission than restrictive procedures

  • a 3 year follow-up of cohort of 256 of 316 randomised patients found metabolic/bariatric surgery is more effective than medical/lifestyle intervention in remission of type 2 diabetes (HbA1c <=6.5% for 3 months without usual glucose-lowering therapy in 37.5% vs. 2.6%, p<0.001)(5)

Principles of metabolic surgery:

  • the finding that glucose homeostasis can be achieved with a weight loss-independent mechanism immediately after bariatric surgery (6,7), especially gastric bypass, has led to the paradigm of metabolic surgery

  • mechanisms of metabolic gastrointestinal surgery are thought to depend on the dramatic entero-hormonal changes after physio-anatomical re-arrangement of the gastrointestinal tract. However, data have shown that weight loss is still the cornerstone of diabetes remission

  • considering weight loss-independent mechanisms for diabetes improvement, metabolic gastrointestinal surgery is now being performed for mildly obese or even overweight patients (BMI < 35 kg/m2), with a focus on diabetes rather than obesity (7)

NICE state (8):

  • for recent onset type 2 diabetics
    • offer an expedited assessment for bariatric surgery to people with a BMI of 35 or over who have recent-onset type 2 diabetes as long as they are also receiving or will receive assessment in a tier 3 service (or equivalent

    • consider an assessment for bariatric surgery for people with a BMI of 30-34.9 who have recent-onset type 2 diabetes as long as they are also receiving or will receive assessment in a tier 3 service (or equivalent)

    • consider an assessment for bariatric surgery for people of Asian family origin who have recent-onset type 2 diabetes at a lower BMI than other populations as long as they are also receiving or will receive assessment in a tier 3 service (or equivalent)

  • bariatric surgery is a treatment option for people with obesity per se if all of the following criteria are fulfilled:
    • they have a BMI of 40 kg/m2 or more, or between 35 kg/m2 and 40 kg/m2 and other significant disease (for example, type 2 diabetes or high blood pressure) that could be improved if they lost weight
      • all appropriate non-surgical measures have been tried but the person has not achieved or maintained adequate, clinically beneficial weight loss
      • the person has been receiving or will receive intensive management in a tier 3 service
      • the person is generally fit for anaesthesia and surgery
      • the person commits to the need for long-term follow-up

Reference:

  1. Colditz, GA, Willett, WC, et al. (1995). Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Intern. Med. 122: 481-6
  2. PHE (2014).Adult obesity and type 2 diabetes
  3. Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013;347:934
  4. Brethauer SA et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013 Oct;258(4):628-36; discussion 636-7.
  5. Kirwan JP et al. Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). Diabetes Care 2022; dc212441. https://doi.org/10.2337/dc21-2441
  6. Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults.BMJ. 2014 Aug 27;349
  7. Pok EH, Lee WJP.Gastrointestinal metabolic surgery for the treatment of type 2 diabetes mellitus. World J Gastroenterol. 2014 Oct 21;20(39):14315-14328.
  8. NICE (November 2014).Obesity: identification, assessment and management of overweight and obesity in children, young people and adults

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.